Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Use of Avatrombopag in Patients with Immune Thrombocytopenia: Interim Analysis of the Phase 4 Adopt Study

María Eva Mingot-Castellano, María Teresa Alvarez-Román, María Luisa Lozano, Wolfgang Miesbach, Hafiz Qureshi, Vickie McDonald, Milica Putnik, Jessica Zhang, Nina Skuban, Viridiana Cano Garcia, Stefan Lethagen

Blood (2024) 144 (Supplement 1): 714.

https://doi.org/10.1182/blood-2024-203491

Published: 2024

Journal Articles

A First Report from the COMPLETE Study on the Real-World Effectiveness of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Régis Peffault de Latour, Roochi Trikha, Carmen Gonzalez Gonzalez, Matthias Nölte, Håkan Malmström, Stefan Lethagen

Blood (2024) 144 (Supplement 1): 5669.

https://doi.org/10.1182/blood-2024-194458

Published: 2024

Journal Articles

Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study

Lynn Malec, An Van Damme, Anthony K. C. Chan, Mariya Spasova, Nisha Jain, Charlotte Sensinger, Jennifer Dumont, Stefan Lethagen, Manuel Carcao, Flora Peyvandi

Blood (2023) 141 (16): 1982–1989.

https://doi.org/10.1182/blood.2022017780

Published: 2023

Includes: Supplemental data

Journal Articles

Efficacy of rFVIIIFc for First-Time Immune Tolerance Induction (ITI) Therapy: Final Results from the Global, Prospective VerITI-8 Study

Lynn Malec, An Van Damme, Anthony Chan, Mariya Spasova, Nisha Jain, Charlotte Sensinger, Jennifer Dumont, Stefan Lethagen, Manuel Carcao, Flora Peyvandi

Blood (2021) 138 (Supplement 2): LBA-5.

https://doi.org/10.1182/blood-2021-155156

Published: 2021

Journal Articles

Clinical Outcomes of Weekly Prophylaxis with rFVIIIFc: Longitudinal Analysis of the A-LONG and ASPIRE Study Population

Amy D. Shapiro, MD, Alok Srivastava, MD, Margaret V. Ragni, MD MPH, Ingrid Pabinger, MD, Stefan Lethagen, Elisa Tsao, Desilu Glazebrook, Doris Quon

Blood (2017) 130 (Supplement 1): 2368.

https://doi.org/10.1182/blood.V130.Suppl_1.2368.2368

Published: 2017

Journal Articles

Longitudinal Analysis of Long-Term Safety and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIFc) in Adults/Adolescents with Severe Hemophilia a

Barbara Konkle, MD, K John Pasi, David J Perry, Johnny Mahlangu, Savita Rangarajan, Simon A Brown, Hideji Hanabusa, Ingrid Pabinger, Lynda M Cristiano, Elisa Tsao, Bent Winding, Desilu Glazebrook, Stefan Lethagen, Shannon Jackson

Blood (2016) 128 (22): 1413.

https://doi.org/10.1182/blood.V128.22.1413.1413

Published: 2016

Journal Articles

Longitudinal Analysis of Long-Term Safety and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Children with Severe Hemophilia a

Guy Young, Raina Liesner, K John Pasi, Beatrice Nolan, Stefan Lethagen, Lynda M Cristiano, Elisa Tsao, Bent Winding, Johnny Mahlangu

Blood (2016) 128 (22): 1414.

https://doi.org/10.1182/blood.V128.22.1414.1414

Published: 2016

Journal Articles

Clinical Outcomes in Adults/Adolescents with Hemophilia B Treated Long Term with Recombinant Factor IX Fc Fusion Protein (rFIXFc) Prophylaxis: Interim Results of the B-Yond Extension Study

Tadashi Matsushita, Johnny Mahlangu, Amy D Shapiro, K John Pasi, Margaret V. Ragni, MD, Margareth C Ozelo, Johannes Oldenburg, Prof, Ross I Baker, Huixing Yuan, Alejandra Ramirez-Santiago, Francesca Ferrante, Stefan Lethagen

Blood (2016) 128 (22): 1416.

https://doi.org/10.1182/blood.V128.22.1416.1416

Published: 2016

Journal Articles

Long-Term Efficacy and Quality of Life with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia a

Michael Wang, MD, K John Pasi, Ingrid Pabinger, Prof, Bryce A. Kerlin, Roshni Kulkarni, MD, Beatrice Nolan, Raina Liesner, Simon A Brown, Hideji Hanabusa, Elisa Tsao, Bent Winding, Stefan Lethagen, Nisha Jain

Blood (2016) 128 (22): 3791.

https://doi.org/10.1182/blood.V128.22.3791.3791

Published: 2016

Journal Articles

Long Term Safety and Efficacy of Recombinant Factor IX Fc Fusion Protein (rFIXFc) Prophylaxis in Children with Hemophilia B: Interim Results of the B-Yond Extension Study

Jonathan M. Ducore, Kathelijn Fischer, Roshni Kulkarni, MD, Beatrice Nolan, Carolyn M. Bennett, David J Perry, Huixing Yuan, Alejandra Ramirez-Santiago, Francesca Ferrante, Stefan Lethagen

Blood (2016) 128 (22): 4976.

https://doi.org/10.1182/blood.V128.22.4976.4976

Published: 2016

Journal Articles

Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: Molecular and Clinical Markers for the Diagnosis and Management of Type 1 VWD (MCMDM-1VWD)

Blood (2008) 111 (10): 4979–4985.

https://doi.org/10.1182/blood-2007-09-110940

Published: 2008

Journal Articles

Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD

Blood (2008) 111 (7): 3531–3539.

https://doi.org/10.1182/blood-2007-08-109231

Published: 2008

Includes: Supplemental data

Journal Articles

Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD)

Blood (2006) 109 (1): 112–121.

https://doi.org/10.1182/blood-2006-05-020784

Published: 2006

Includes: Supplemental data

Journal Articles

Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome

Diana Karpman, Domniki Papadopoulou, Kajsa Nilsson, Ann-Christine Sjögren, Carl Mikaelsson, Stefan Lethagen

Blood (2001) 97 (10): 3100–3108.

https://doi.org/10.1182/blood.V97.10.3100

Published: 2001

NARROW

Use of Avatrombopag in Patients with Immune Thrombocytopenia: Interim Analysis of the Phase 4 Adopt Study

A First Report from the COMPLETE Study on the Real-World Effectiveness of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study

Efficacy of rFVIIIFc for First-Time Immune Tolerance Induction (ITI) Therapy: Final Results from the Global, Prospective VerITI-8 Study

Clinical Outcomes of Weekly Prophylaxis with rFVIIIFc: Longitudinal Analysis of the A-LONG and ASPIRE Study Population

Longitudinal Analysis of Long-Term Safety and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIFc) in Adults/Adolescents with Severe Hemophilia a

Longitudinal Analysis of Long-Term Safety and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Children with Severe Hemophilia a

Clinical Outcomes in Adults/Adolescents with Hemophilia B Treated Long Term with Recombinant Factor IX Fc Fusion Protein (rFIXFc) Prophylaxis: Interim Results of the B-Yond Extension Study

Long-Term Efficacy and Quality of Life with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia a

Long Term Safety and Efficacy of Recombinant Factor IX Fc Fusion Protein (rFIXFc) Prophylaxis in Children with Hemophilia B: Interim Results of the B-Yond Extension Study

Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: Molecular and Clinical Markers for the Diagnosis and Management of Type 1 VWD (MCMDM-1VWD)

Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD

Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD)

Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only